TORONTO, July 25, 2019 -- Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company”), developer of the PATSCAN™ Multi-Sensor Covert Threat Detection Platform (“PATSCAN”),  is pleased to announce that it has completed an exclusive global commercial...
Tailwinds Take: with an aggressive timeline, ITUS' CAR-T therapy could be in humans in less than a year from today. If successful, it would be the first CAR-T for solid cancer, a market far bigger than any approved CAR-T...
Tailwinds' Take: with the launch of WiSA ready in Best Buy coming soon, expanding the eco-system is important to driving the standard. Expect to hear more about the launch and revenue ramp in coming weeks and months. SAN JOSE, CA...
The markets are celebrating the pending agreement between China and the United States to end the trade war. This follows the US Federal Reserve signalling a pause in raising interest rates. The euphoria is bringing the bulls out of hiding....
Yesterday Chromadex announced the pricing of a private placement for $23M dollars. This deal was significant to the Company in that they have padded their purse at a time when they are rolling out Tru Niagen on a global...
Tailwinds' Take: this is a positive step for PeerStream, whose blockchain business is growing rapidly. It's a landgrab in the blockchain services world right now and PEER is staking their claim. NEW YORK, NY & Westport, CT, Oct. 17, 2018...
SAN JOSE, Calif., Jan. 29, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it presented positive data from its early cancer detection technology on January 26th at the American Society of Clinical Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) Clinical...
Tailwinds' Take: these patents have been successfully defended in the past against big firms like Sony, so I expect they will be able to win again. Any settlement is likely in seven figures, but probably not more than $15M,...
Today in a press release, Harrow announced the Series A financing of their (formerly) wholly owned subsidiary, Melt Pharmaceuticals. This is a very positive announcement for Harrow and I believe the value of MELT is in no way reflected...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.